Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1248.65
₹7.90(0.63%)
At close: 4:00 PM EDT
₹1248.65
₹7.90(0.63%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹1,800.00
Previous CloseN/A
Volume79.36K
Average Volume (3M)12.81K
Market Cap
₹164.17B
Enterprise Value₹101.96K
Total Cash (Recent Filing)₹4.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)59.9
Beta1.16
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)26.24
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.65
Revenue Forecast (FY)₹12.94B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage reduces financial risk and preserves flexibility for capacity expansion, research, or working-capital needs. Steadily increasing equity and consistently positive returns also support resilience through changes in demand.
Solid Cash GenerationPositive operating cash flow that generally exceeds reported earnings indicates reasonable earnings quality and internal funding capacity. This can support investment and reduce reliance on external financing as the business develops.
Niche API CapabilitiesSpecialization in complex fermentation-based APIs can create technical and regulatory barriers to entry and support durable customer relationships. Exposure to immunosuppressant and oncology markets also provides relevance in important therapeutic categories.
Bears Say
Revenue ContractionA reversal from earlier expansion signals weaker operating momentum and creates uncertainty about demand, customer orders, or market conditions. Sustained contraction could reduce scale benefits and limit the company’s ability to absorb fixed manufacturing costs.
Margin NormalizationLower margins indicate that prior peak profitability may not be fully sustainable. Continued pressure from product mix, pricing, input costs, or manufacturing utilization could reduce earnings conversion even if the company maintains positive revenue and gross profit.
Cash Flow VolatilityUneven free cash flow suggests periodic swings in reinvestment or working-capital requirements. Although operating cash generation is solid, volatility can make funding capacity less predictable and may constrain flexibility during expansion or demand slowdowns.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹1800.00 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹164.17B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 86 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Jul 31, 2026. The company reported ₹5.6 earnings per share for the quarter, missing the consensus estimate of ₹7.333 by -₹1.733.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Annually dividend of ₹7.55 which represents an annual dividend yield of 0.48%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹5.6 in its last earnings report, missing expectations of ₹7.333. Following the earnings report the stock price went up 6.533%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―
Anthem Biosciences Limited
―